Sanofi India Ltd
NSE:SANOFI

Watchlist Manager
Sanofi India Ltd Logo
Sanofi India Ltd
NSE:SANOFI
Watchlist
Price: 4 271 INR -1.37% Market Closed
Market Cap: 98.4B INR

Sanofi India Ltd
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Sanofi India Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Sanofi India Ltd
NSE:SANOFI
Pre-Tax Income
₹4.8B
CAGR 3-Years
-16%
CAGR 5-Years
-6%
CAGR 10-Years
3%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Pre-Tax Income
₹75.3B
CAGR 3-Years
20%
CAGR 5-Years
30%
CAGR 10-Years
15%
Cipla Ltd
NSE:CIPLA
Pre-Tax Income
₹70.4B
CAGR 3-Years
25%
CAGR 5-Years
22%
CAGR 10-Years
12%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Pre-Tax Income
₹140.7B
CAGR 3-Years
40%
CAGR 5-Years
53%
CAGR 10-Years
11%
Lupin Ltd
NSE:LUPIN
Pre-Tax Income
₹53.9B
CAGR 3-Years
164%
CAGR 5-Years
39%
CAGR 10-Years
6%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Pre-Tax Income
₹28.8B
CAGR 3-Years
32%
CAGR 5-Years
16%
CAGR 10-Years
4%
No Stocks Found

Sanofi India Ltd
Glance View

Market Cap
98.4B INR
Industry
Pharmaceuticals

Sanofi India Ltd., a prominent name in the pharmaceutical landscape, operates as a subsidiary of Sanofi S.A., the global healthcare giant headquartered in France. Its roots in India trace back to the early 1950s when it began importing and distributing vaccines. Over the decades, Sanofi India has evolved into a comprehensive provider of high-quality drugs, contributing significantly to the nation’s healthcare ecosystem. The company focuses primarily on therapeutic segments such as diabetes, cardiovascular diseases, oncology, and vaccines, boasting a robust portfolio of prescription medicines and over-the-counter products. By leveraging a vast network of healthcare professionals and engaging in continuous clinical research and development, Sanofi India ensures its position at the forefront of medical innovation, adhering to a global strategy of patient-oriented solutions and a commitment to improving health outcomes. Sanofi India's revenue model revolves around its diversified product portfolio, addressing a spectrum of critical health areas. The company generates income through the sale of its flagship products, which include insulin for diabetes management, anti-allergy medications, and innovative therapies for rare diseases, among others. While the domestic market plays a crucial role in its financial framework, Sanofi India also taps into international markets, exporting its high-quality pharmaceutical products across borders. The profitability of the company is further bolstered by its commitment to research and development, enabling it to introduce new drugs and therapies, thus continually expanding its market share. By maintaining strong distribution channels and fostering collaborations with medical institutions and regulatory bodies, Sanofi India ensures its products reach a broad consumer base, perpetuating its growth trajectory in the competitive pharmaceutical scene.

SANOFI Intrinsic Value
3 259.24 INR
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Sanofi India Ltd's Pre-Tax Income?
Pre-Tax Income
4.8B INR

Based on the financial report for Sep 30, 2025, Sanofi India Ltd's Pre-Tax Income amounts to 4.8B INR.

What is Sanofi India Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
3%

Over the last year, the Pre-Tax Income growth was -3%. The average annual Pre-Tax Income growth rates for Sanofi India Ltd have been -16% over the past three years , -6% over the past five years , and 3% over the past ten years .

Back to Top